Form 4: Corcept Therapeutics Director James Wilson Granted 25,000 Stock Options

Corcept Therapeutics Inc. director James N. Wilson was granted 25,000 stock options with an exercise price of $72.27, vesting monthly over one year.

Summary

• James N. Wilson, a Director of Corcept Therapeutics Inc. (CORT), acquired 25,000 derivative securities in the form of stock options.
• The transaction date for this acquisition was June 10, 2025.
• Each stock option has an exercise price of $72.27.
• The options are exercisable ratably in equal installments on each monthly anniversary of June 10, 2025, over a one-year period.
• Vesting is subject to Mr. Wilson's continued service on each monthly vesting date.
• The expiration date for these stock options is June 10, 2035.
• Following this transaction, Mr. Wilson beneficially owns 25,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The sentiment is positive as the grant of stock options aligns the director's interests with shareholders and is a standard practice for incentivizing and retaining key personnel. It does not indicate any negative operational or financial news.

Positives

• The grant of stock options to Director James N. Wilson aligns his interests with those of the shareholders, as the value of his options will increase with the company's stock price.
• This type of equity compensation is a standard practice for retaining and incentivizing key board members.

Future Outlook

The vesting schedule of the stock options over a one-year period indicates an expectation of continued service from Director James N. Wilson, aligning his long-term commitment with the company's performance.

Management Comments

• The filing was signed by Joseph Douglas Lyon, as attorney-in-fact for James N. Wilson.

Industry Context

The granting of stock options to directors is a common practice across various industries, including the pharmaceutical and biotechnology sectors, serving as a key component of executive and board compensation packages to align leadership incentives with long-term shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard form of equity compensation for directors in publicly traded companies, including those in the pharmaceutical industry like Corcept Therapeutics.
• The vesting schedule of ratable monthly installments over one year is a common approach to ensure continued service and align director interests with sustained company performance, comparable to practices at companies such as Pfizer, Johnson & Johnson, or Merck, which also utilize equity-based incentives for their board members.

Related Party Transactions

• The grant of 25,000 stock options to James N. Wilson, a director of Corcept Therapeutics Inc., constitutes a transaction with a related party (an insider) as part of his compensation for board service.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial incentives with the company's stock performance, potentially benefiting shareholders if the stock price increases.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• James N. Wilson's continued service to Corcept Therapeutics Inc. is required for the monthly vesting of his stock options over the next year.

Key Dates

Recommendation

Keywords

Corcept Therapeutics, CORT, Stock Options, Director Compensation, Insider Transaction, SEC Form 4, Equity Grant, Executive Compensation